This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Book Profits on Health Care Stocks

NEW YORK ( TheStreet) -- I have been looking at economic sectors that are overvalued recently, and another sector where investors should take profits is health care.

At, we call this sector the medical sector and consider it to be 5.5% overvalued. Only three other sectors are more overvalued: Utilities by the largest amount, 13.4%, followed by consumer staples at 7.7% and finance at 6%.

Today, I will focus on the top 10 weighted stocks in the Health Care Select Sector SPDR Fund (XLV), which contains 52 equity components and is my benchmark for the sector. On July 27, the XLV tested an all-time high of $38.90 after rallying 31.2% from its year-ago low of $29.64. XLV is up 79.8% since March 2009.

This strength should be difficult to sustain given the depleted new drug pipeline among the major pharmaceutical companies. The most notable prescription drug that recently came off patent is Pfizer's (PFE - Get Report) blockbuster cholesterol drug Lipitor. Now patients can use a Lipitor generic. Also, the companies involved with health care insurance must cope with the Affordable Care Act.

This week, Pfizer and Johnson & Johnson (JNJ - Get Report) ended plans to develop an Alzheimer's drug after a second trial failure. This drug held the promise of being able to slow the progress of the disease, but the latest trial showed it failed to do so.

On a positive note, after the market close on Tuesday, Express Scripts (ESRX - Get Report) reported that, while its second-quarter earnings fell 49% on acquisition-related costs, it's adjusted earnings per share were 88 cents, above analyst estimates, and revenue more than doubled. In addition, the pharmacy-benefits manager raised earnings guidance for 2012. The stock surged to a new year-to-date high of $59.95 in after hours trading.

Source: Thomson Reuters

The weekly chart above shows that XLV has a positive but overbought pattern with XLV above its five-week modified moving average at $38.02 with overbought momentum (12x3x3 weekly slow stochastic) reading. The 200-week simple moving average is a major support at $31.11. My annual value levels are $36.71 and $34.12 with weekly, monthly and quarterly risky levels at $39.48, $40.06 and $40.84.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
XLV $71.81 -0.95%
AMGN $157.10 -1.70%
ESRX $84.23 -2.90%
JNJ $99.13 -1.50%
PFE $34.32 -1.40%


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs